LONDON
Annalisa Jenkins
Annalisa Jenkins, M.B.B.S., F.R.C.P. is a biopharma thought leader with over 25 years of industry experience. Dr. Jenkins has extensive recent experience in building and financing biotech companies pursuing cures for the most challenging rare diseases to address important medical issues globally. She has consistently built and led teams advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. In addition, she is an advocate for diversity and inclusion, particularly for women in science. Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years - including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Oncimmune, AVROBIO, COMPASS Pathways, AOBiome, AgeX, ADOR Diagnostics, MedCity, DMNoMore, Conduit Connect, Affimed, Cocoon Biotech Inc. (Non-Executive Chair), and Kuur Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration, which advises FDA leadership on complex scientific and technical issues, board member at Faster Cures a center of The Milken Institute and Chair of The Court The London School of Hygiene and Tropical Medicine.
Denise Scots-Knight
Denise Scots-Knight is the CEO and a board member of Mereo Biopharma, an oncology and rare disease company founded in July 2015 which is listed on the LSE (MPH) and NASDQ (MREO). She was previously Head of Life Sciences investment at Nomura and an Investment Manager at Rothschild Asset Management following a period in R&D management. She is an experienced Non-Executive Board member in the US and EU serving on the boards of public and private companies, has a PhD and BSc in Biochemistry and was a Fulbright scholar. She currently serves as a Non-Executive Board Member of Elanco Inc an animal healthcare company listed on the NYSE (ELAN).
Catherine Moukheibir
Catherine Moukheibir has 20 years of experience integrating corporate and financial strategies in European pharma and biotech companies, following from a 15-year career in management consulting and investment banking in the US and London. She is Chairman of Medday since 2016 and was recently appointed CEO. Her relevant expertise includes six years on the Executive Board of Innate Pharma, during which time Innate entered into emblematic partnerships with Bristol-Myers Squibb, Novo Nordisk and AstraZeneca. She was Chairman of Creabilis (acquired by Sienna Pharmaceuticals); non-executive Director and Chair of the Audit Committee at Zealand Pharma during which time Zealand restructured and reinforced the management team, listed on Nasdaq and monetised the Sanofi royalty stream; non-executive Director and member of the transaction committee and audit committees of Ablynx, during which time Ablynx listed on Nasdaq and was acquired by Sanofi. In addition to her Medday responsibilities, Catherine is currently a non-executive Director of Orphazyme, Genkyotex, Ironwood and Kymab. Earlier she was the Chief Financial Officer of Movetis, overseeing the company’s IPO on Euronext in December 2009 and subsequent sale to Shire. Catherine Moukheibir holds an MA and an MBA from Yale University.